[{"address1": "770 Lindaro Street", "city": "San Rafael", "state": "CA", "zip": "94901", "country": "United States", "phone": "415 506 6700", "website": "https://www.biomarin.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.", "fullTimeEmployees": 3401, "companyOfficers": [{"maxAge": 1, "name": "Mr. Alexander  Hardy", "age": 55, "title": "President, CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 1715598, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian R. Mueller CPA", "age": 50, "title": "CFO & Executive VP", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 1074819, "exercisedValue": 2474925, "unexercisedValue": 1185108}, {"maxAge": 1, "name": "Dr. C. Greg Guyer Ph.D.", "age": 62, "title": "Executive VP & CTO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1114215, "exercisedValue": 0, "unexercisedValue": 876749}, {"maxAge": 1, "name": "Dr. Henry J. Fuchs M.D., Ph.D.", "age": 66, "title": "Advisor", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1411725, "exercisedValue": 0, "unexercisedValue": 3725258}, {"maxAge": 1, "name": "Ms. Erin  Burkhart", "age": 45, "title": "Group VP & Chief Accounting Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Eggan Ph.D.", "title": "Chief Scientific Officer & Senior VP of Research and Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Traci  McCarty", "title": "Group Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. George Eric Davis J.D.", "age": 53, "title": "Executive VP, Chief Legal Officer, General Counsel & Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1231702, "exercisedValue": 2113615, "unexercisedValue": 4885664}, {"maxAge": 1, "name": "Ms. Amy  Wireman", "title": "Executive VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ganesh  Vedantham Ph.D.", "title": "Senior Vice President of Technical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 5, "overallRisk": 3, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://investors.bmrn.com/index.cfm", "maxAge": 86400, "priceHint": 2, "previousClose": 64.42, "open": 64.68, "dayLow": 63.56, "dayHigh": 65.47, "regularMarketPreviousClose": 64.42, "regularMarketOpen": 64.68, "regularMarketDayLow": 63.56, "regularMarketDayHigh": 65.47, "beta": 0.283, "trailingPE": 39.066265, "forwardPE": 15.596065, "volume": 986470, "regularMarketVolume": 986470, "averageVolume": 1488468, "averageVolume10days": 1075090, "averageDailyVolume10Day": 1075090, "bid": 60.69, "ask": 64.92, "bidSize": 100, "askSize": 600, "marketCap": 12359308288, "fiftyTwoWeekLow": 60.63, "fiftyTwoWeekHigh": 94.85, "priceToSalesTrailing12Months": 4.489708, "fiftyDayAverage": 64.8706, "twoHundredDayAverage": 74.753, "currency": "USD", "enterpriseValue": 12031551488, "profitMargins": 0.11708, "floatShares": 179170905, "sharesOutstanding": 190583008, "sharesShort": 4504362, "sharesShortPriorMonth": 4542138, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.023599999, "heldPercentInsiders": 0.0094800005, "heldPercentInstitutions": 0.98688006, "shortRatio": 2.67, "shortPercentOfFloat": 0.0238, "impliedSharesOutstanding": 190583008, "bookValue": 28.409, "priceToBook": 2.2827272, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": 1.627, "netIncomeToCommon": 322291008, "trailingEps": 1.66, "forwardEps": 2.99, "enterpriseToRevenue": 4.371, "enterpriseToEbitda": 28.237, "52WeekChange": -0.26863652, "SandP52WeekChange": 0.22894537, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BMRN", "underlyingSymbol": "BMRN", "shortName": "BioMarin Pharmaceutical Inc.", "longName": "BioMarin Pharmaceutical Inc.", "firstTradeDateEpochUtc": 932995800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bcd60339-c59b-3a43-af89-b10253407aca", "messageBoardId": "finmb_25605", "gmtOffSetMilliseconds": -18000000, "currentPrice": 64.85, "targetHighPrice": 127.0, "targetLowPrice": 65.0, "targetMeanPrice": 96.855, "targetMedianPrice": 94.5, "recommendationMean": 1.65385, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 930444032, "totalCashPerShare": 4.882, "ebitda": 426088992, "totalDebt": 602686976, "quickRatio": 2.387, "currentRatio": 4.271, "totalRevenue": 2752808960, "debtToEquity": 11.133, "revenuePerShare": 14.529, "returnOnAssets": 0.029979998, "returnOnEquity": 0.06252, "grossProfits": 1441218048, "freeCashflow": 144674752, "operatingCashflow": 414696992, "earningsGrowth": 1.607, "revenueGrowth": 0.283, "grossMargins": 0.52354, "ebitdaMargins": 0.15478, "operatingMargins": 0.15272, "financialCurrency": "USD", "trailingPegRatio": 0.4058, "__fetch_time": "2025-02-15"}]